Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives.

Askalsky P, Iosifescu DV.

Neuropsychiatr Dis Treat. 2019 Nov 22;15:3255-3272. doi: 10.2147/NDT.S188906. eCollection 2019. Review.

2.

Reported Side Effects, Weight and Blood Pressure, After Repeated Sessions of Transcranial Photobiomodulation.

Cassano P, Caldieraro MA, Norton R, Mischoulon D, Trinh NH, Nyer M, Dording C, Hamblin MR, Campbell B, Iosifescu DV.

Photobiomodul Photomed Laser Surg. 2019 Oct;37(10):651-656. doi: 10.1089/photob.2019.4678.

PMID:
31647774
3.

Neural Predictors of the Antidepressant Placebo Response.

Rette D, McDonald E, Iosifescu DV, Collins KA.

Pharmaceuticals (Basel). 2019 Oct 19;12(4). pii: E158. doi: 10.3390/ph12040158. Review.

4.

Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI.

J Affect Disord. 2020 Jan 1;260:131-139. doi: 10.1016/j.jad.2019.09.017. Epub 2019 Sep 3.

PMID:
31494365
5.

Protein Biomarkers in Major Depressive Disorder: An Update.

Woods AG, Wormwood KL, Iosifescu DV, Murrough J, Darie CC.

Adv Exp Med Biol. 2019;1140:585-600. doi: 10.1007/978-3-030-15950-4_35.

PMID:
31347073
6.

Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials.

Köhler-Forsberg O, Sylvia LG, Bowden CL, Calabrese JR, Thase ME, Shelton RC, McInnis M, Tohen M, Kocsis JH, Ketter TA, Friedman ES, Deckersbach T, Ostacher MJ, Iosifescu DV, McElroy S, Nierenberg AA.

Acta Neuropsychiatr. 2019 Aug;31(4):230-234. doi: 10.1017/neu.2019.19. Epub 2019 Jun 6.

PMID:
31169098
7.

Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.

Costi S, Soleimani L, Glasgow A, Brallier J, Spivack J, Schwartz J, Levitch CF, Richards S, Hoch M, Wade E, Welch A, Collins KA, Feder A, Iosifescu DV, Charney DS, Murrough JW.

Neuropsychopharmacology. 2019 Sep;44(10):1812-1819. doi: 10.1038/s41386-019-0365-0. Epub 2019 Mar 11.

PMID:
30858518
8.

The Influence of Depression on the Psychometric Properties of the Maslach Burnout Inventory-Human Services Survey: A Cross-Sectional Study With Nursing Assistants.

Trigo TR, de Freitas CCS, Wang YP, Ribeiro FG, de Lucia MCS, Siqueira JO, Iosifescu DV, Hallak JEC, Fraguas R.

Front Psychiatry. 2018 Dec 18;9:695. doi: 10.3389/fpsyt.2018.00695. eCollection 2018.

9.

Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2019 Jan 7. doi: 10.1038/s41380-018-0311-2. [Epub ahead of print]

PMID:
30617276
10.

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.

Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI.

Depress Anxiety. 2019 Mar;36(3):235-243. doi: 10.1002/da.22875. Epub 2018 Dec 30.

PMID:
30597688
11.

The Prevalence of Mitral Valve Prolapse in Panic Disorder: A Meta-Analysis.

Tural U, Iosifescu DV.

Psychosomatics. 2019 Jul - Aug;60(4):393-401. doi: 10.1016/j.psym.2018.10.002. Epub 2018 Oct 31.

PMID:
30448200
12.

Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.

Tan A, Costi S, Morris LS, Van Dam NT, Kautz M, Whitton AE, Friedman AK, Collins KA, Ahle G, Chadha N, Do B, Pizzagalli DA, Iosifescu DV, Nestler EJ, Han MH, Murrough JW.

Mol Psychiatry. 2018 Nov 1. doi: 10.1038/s41380-018-0283-2. [Epub ahead of print]

13.

Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial.

Cassano P, Petrie SR, Mischoulon D, Cusin C, Katnani H, Yeung A, De Taboada L, Archibald A, Bui E, Baer L, Chang T, Chen J, Pedrelli P, Fisher L, Farabaugh A, Hamblin MR, Alpert JE, Fava M, Iosifescu DV.

Photomed Laser Surg. 2018 Dec;36(12):634-646. doi: 10.1089/pho.2018.4490. Epub 2018 Oct 20.

PMID:
30346890
14.

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2018 Oct 3. doi: 10.1038/s41380-018-0256-5. [Epub ahead of print] Erratum in: Mol Psychiatry. 2019 Jan 7;:.

15.

Effects of transcranial photobiomodulation with near-infrared light on sexual dysfunction.

Cassano P, Dording C, Thomas G, Foster S, Yeung A, Uchida M, Hamblin MR, Bui E, Fava M, Mischoulon D, Iosifescu DV.

Lasers Surg Med. 2019 Feb;51(2):127-135. doi: 10.1002/lsm.23011. Epub 2018 Sep 17.

PMID:
30221776
16.

Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder.

Gould F, Dunlop BW, Rosenthal JB, Iosifescu DV, Mathew SJ, Neylan TC, Rothbaum BO, Nemeroff CB, Harvey PD.

Arch Clin Neuropsychol. 2019 Jun 1;34(4):539-547. doi: 10.1093/arclin/acy064.

17.

Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study.

Schneier FR, Slifstein M, Whitton AE, Pizzagalli DA, Reinen J, McGrath PJ, Iosifescu DV, Abi-Dargham A.

Biol Psychiatry. 2018 Oct 15;84(8):563-573. doi: 10.1016/j.biopsych.2018.05.014. Epub 2018 May 25.

18.

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults.

Richards C, Iosifescu DV, Mago R, Sarkis E, Geibel B, Dauphin M, McIntyre RS, Weisler R, Brawman-Mintzer O, Gu J, Madhoo M.

J Clin Psychopharmacol. 2018 Aug;38(4):336-343. doi: 10.1097/JCP.0000000000000897.

19.

A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo.

Murrough JW, Huryk KM, Mao X, Iacoviello B, Collins K, Nierenberg AA, Kang G, Shungu DC, Iosifescu DV.

J Affect Disord. 2018 Apr 1;230:56-64. doi: 10.1016/j.jad.2017.12.067. Epub 2018 Jan 2.

PMID:
29407539
20.

A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression.

Iacoviello BM, Murrough JW, Hoch MM, Huryk KM, Collins KA, Cutter GR, Iosifescu DV, Charney DS.

NPJ Digit Med. 2018;1. pii: 21. doi: 10.1038/s41746-018-0025-5. Epub 2018 Jun 6.

21.

A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder.

Sayed S, Van Dam NT, Horn SR, Kautz MM, Parides M, Costi S, Collins KA, Iacoviello B, Iosifescu DV, Mathé AA, Southwick SM, Feder A, Charney DS, Murrough JW.

Int J Neuropsychopharmacol. 2018 Jan 1;21(1):3-11. doi: 10.1093/ijnp/pyx109.

22.

Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI.

Brain Stimul. 2018 Jan - Feb;11(1):75-84. doi: 10.1016/j.brs.2017.09.010. Epub 2017 Sep 23.

23.

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.

Richards C, Iosifescu DV, Mago R, Sarkis E, Reynolds J, Geibel B, Dauphin M.

J Psychopharmacol. 2017 Sep;31(9):1190-1203. doi: 10.1177/0269881117722998. Epub 2017 Aug 31.

24.

Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.

Murrough JW, Wade E, Sayed S, Ahle G, Kiraly DD, Welch A, Collins KA, Soleimani L, Iosifescu DV, Charney DS.

J Affect Disord. 2017 Aug 15;218:277-283. doi: 10.1016/j.jad.2017.04.072. Epub 2017 Apr 29.

PMID:
28478356
25.

Ketamine and ECT: better alone than together?

Kellner CH, Iosifescu DV.

Lancet Psychiatry. 2017 May;4(5):348-349. doi: 10.1016/S2215-0366(17)30099-8. Epub 2017 Mar 27. No abstract available.

26.

Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.

Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV, Charney DS, Murrough JW.

Transl Psychiatry. 2017 Mar 21;7(3):e1065. doi: 10.1038/tp.2017.31.

27.

The influence of depression on personality traits in patients with fibromyalgia: a case-control study.

Santos DM, Lage LV, Jabur EK, Kaziyama HHS, Iosifescu DV, De Lucia MCS, Fráguas R.

Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 105(3):13-19. Epub 2016 Oct 20.

PMID:
27782872
28.

Ketamine Treatment and Global Brain Connectivity in Major Depression.

Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, DeWilde KE, Wong E, Anticevic A, Tang CY, Iosifescu DV, Charney DS, Murrough JW.

Neuropsychopharmacology. 2017 May;42(6):1210-1219. doi: 10.1038/npp.2016.186. Epub 2016 Sep 8.

29.

The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy.

Iosifescu DV, Neborsky RJ, Valuck RJ.

Neuropsychiatr Dis Treat. 2016 Aug 25;12:2131-42. doi: 10.2147/NDT.S113712. eCollection 2016.

30.

Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression.

Harper DG, Jensen JE, Ravichandran C, Perlis RH, Fava M, Renshaw PF, Iosifescu DV.

Neuropsychopharmacology. 2017 Mar;42(4):876-885. doi: 10.1038/npp.2016.180. Epub 2016 Sep 2.

31.

Using Electroencephalography for Treatment Guidance in Major Depressive Disorder.

Wade EC, Iosifescu DV.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Sep;1(5):411-422. doi: 10.1016/j.bpsc.2016.06.002. Epub 2016 Jun 9. Review.

PMID:
29560870
32.

Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder.

Murrough JW, Abdallah CG, Anticevic A, Collins KA, Geha P, Averill LA, Schwartz J, DeWilde KE, Averill C, Jia-Wei Yang G, Wong E, Tang CY, Krystal JH, Iosifescu DV, Charney DS.

Hum Brain Mapp. 2016 Sep;37(9):3214-23. doi: 10.1002/hbm.23235. Epub 2016 May 4.

33.

White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder.

Köhler O, Sylvia LG, Bowden CL, Calabrese JR, Thase M, Shelton RC, McInnis M, Tohen M, Kocsis JH, Ketter TA, Friedman ES, Deckersbach T, Ostacher MJ, Iosifescu DV, McElroy S, Nierenberg AA.

Aust N Z J Psychiatry. 2017 Apr;51(4):355-365. doi: 10.1177/0004867416644508. Epub 2016 Jul 11.

PMID:
27126391
34.

Ketamine for treatment-resistant depression: recent developments and clinical applications.

Schwartz J, Murrough JW, Iosifescu DV.

Evid Based Ment Health. 2016 May;19(2):35-8. doi: 10.1136/eb-2016-102355. Epub 2016 Apr 6. Review.

PMID:
27053196
35.

Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis.

Cassano P, Petrie SR, Hamblin MR, Henderson TA, Iosifescu DV.

Neurophotonics. 2016 Jul;3(3):031404. doi: 10.1117/1.NPh.3.3.031404. Epub 2016 Mar 4. Review.

36.

A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR).

Ostacher MJ, Nierenberg AA, Rabideau D, Reilly-Harrington NA, Sylvia LG, Gold AK, Shesler LW, Ketter TA, Bowden CL, Calabrese JR, Friedman ES, Iosifescu DV, Thase ME, Leon AC, Trivedi MH.

J Psychiatr Res. 2015 Dec;71:126-33. doi: 10.1016/j.jpsychires.2015.10.004. Epub 2015 Oct 9.

37.

Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study.

Cassano P, Cusin C, Mischoulon D, Hamblin MR, De Taboada L, Pisoni A, Chang T, Yeung A, Ionescu DF, Petrie SR, Nierenberg AA, Fava M, Iosifescu DV.

Psychiatry J. 2015;2015:352979. doi: 10.1155/2015/352979. Epub 2015 Aug 19.

38.

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.

Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, Lener M, Kautz M, Kim J, Stern JB, Price RB, Perez AM, Brallier JW, Rodriguez GJ, Goodman WK, Iosifescu DV, Charney DS.

Psychol Med. 2015 Dec;45(16):3571-80. doi: 10.1017/S0033291715001506. Epub 2015 Aug 12.

PMID:
26266877
39.

Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.

Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS.

Brain Stimul. 2015 Jul-Aug;8(4):787-94. doi: 10.1016/j.brs.2015.05.005. Epub 2015 May 22.

PMID:
26143022
40.

Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge.

Iosifescu DV.

J Clin Psychiatry. 2015 Jun;76(6):738-40. doi: 10.4088/JCP.15com09904. No abstract available.

41.

In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature.

Lener MS, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1344:50-65. doi: 10.1111/nyas.12759. Epub 2015 Apr 8. Review.

PMID:
25854817
42.

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.

Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, Wong E, Tang CY, Charney DS, Iosifescu DV.

Transl Psychiatry. 2015 Feb 17;5:e509. doi: 10.1038/tp.2015.10.

43.

The association of post-stroke anhedonia with salivary cortisol levels and stroke lesion in hippocampal/parahippocampal region.

Terroni L, Amaro E Jr, Iosifescu DV, Mattos P, Yamamoto FI, Tinone G, Conforto AB, Sobreiro MF, Guajardo VD, De Lucia MC, Moreira AC, Scaff M, Leite CC, Fraguas R.

Neuropsychiatr Dis Treat. 2015 Feb 3;11:233-42. doi: 10.2147/NDT.S73722. eCollection 2015.

44.

The promise of ketamine for treatment-resistant depression: current evidence and future directions.

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1345:47-58. doi: 10.1111/nyas.12646. Epub 2015 Feb 3. Review.

45.

The influence of depressive symptoms on quality of life after stroke: a prospective study.

Guajardo VD, Terroni L, Sobreiro Mde F, Zerbini MI, Tinone G, Scaff M, Iosifescu DV, de Lucia MC, Fráguas R.

J Stroke Cerebrovasc Dis. 2015 Jan;24(1):201-9. doi: 10.1016/j.jstrokecerebrovasdis.2014.08.020. Epub 2014 Nov 12.

PMID:
25440338
46.

Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.

Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV.

Neuropsychopharmacology. 2015 Mar 13;40(5):1084-90. doi: 10.1038/npp.2014.298.

47.

Ketamine safety and tolerability in clinical trials for treatment-resistant depression.

Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW.

J Clin Psychiatry. 2015 Mar;76(3):247-52. doi: 10.4088/JCP.13m08852.

PMID:
25271445
48.

The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder.

Sylvia LG, Rabideau DJ, Nierenberg AA, Bowden CL, Friedman ES, Iosifescu DV, Thase ME, Ketter T, Greiter EA, Calabrese JR, Leon AC, Ostacher MJ, Reilly-Harrington N.

J Affect Disord. 2014 Dec;169:144-8. doi: 10.1016/j.jad.2014.08.019. Epub 2014 Aug 20.

49.

Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression.

Treadway MT, Waskom ML, Dillon DG, Holmes AJ, Park MTM, Chakravarty MM, Dutra SJ, Polli FE, Iosifescu DV, Fava M, Gabrieli JDE, Pizzagalli DA.

Biol Psychiatry. 2015 Feb 1;77(3):285-294. doi: 10.1016/j.biopsych.2014.06.018. Epub 2014 Jul 3.

50.

Dissociable cortico-striatal connectivity abnormalities in major depression in response to monetary gains and penalties.

Admon R, Nickerson LD, Dillon DG, Holmes AJ, Bogdan R, Kumar P, Dougherty DD, Iosifescu DV, Mischoulon D, Fava M, Pizzagalli DA.

Psychol Med. 2015 Jan;45(1):121-31. doi: 10.1017/S0033291714001123. Epub 2014 May 15.

Supplemental Content

Loading ...
Support Center